Literature DB >> 7966778

A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine.

A M Traish1, N Netsuwan, J Daley, H Padman-Nathan, I Goldstein, I Saenz de Tejada.   

Abstract

In this study we investigated the physiological properties and binding characteristics of alpha-1 adrenergic receptor (alpha 1-AR) in human corpus cavernosum (HCC) in order to identify alpha 1-AR subtypes at the functional protein level. Exposure of tissue strips to norepinephrine (NE) caused concentration-dependent contractions that were partially and noncompetitively inhibited by 10 to 100 microM. of chloroethylclonidine (CEC), an alkylating agent that specifically and irreversibly inactivates alpha 1B-AR and alpha 1C-AR subtypes. Norepinephrine-induced contractions were competitively and effectively inhibited with WB 4101, a competitive, high-affinity antagonist for alpha 1A-AR and alpha 1C-AR subtypes. The CEC-insensitive receptor subtypes bound WB 4101 with high affinity, suggesting the presence of alpha 1A-AR in HCC. Binding of [3H]prazosin and 2-[beta-(4-hydroxy-3-[125I]iodophenyl)-ethylaminomethyl]-tetralone ([125I]HEAT) to membranes of HCC treated with or without CEC demonstrated the presence of two subpopulations: a CEC-sensitive receptor population (40 to 50%), which may represent inactivation of the alpha 1B-AR and alpha 1C-AR subtypes, and a CEC-resistant receptor subpopulation, which is probably the alpha 1A-AR subtype. The physiological and biochemical properties of alpha 1-AR in HCC clearly suggest that the NE-induced contraction of HCC smooth muscle is mediated by more than one alpha 1-AR subtype. It is likely that two or possibly three receptor subtypes are involved in mediating the contraction. Further, it is possible that NE-mediated contraction of trabecular smooth muscle requires synergistic receptor-receptor receptor interactions at the second messenger or at the receptor protein level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7966778     DOI: 10.1097/00005392-199501000-00081

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Evolution in the concept of erection anatomy.

Authors:  Ayman Awad; Bayan Alsaid; Thomas Bessede; Stéphane Droupy; Gérard Benoît
Journal:  Surg Radiol Anat       Date:  2010-08-05       Impact factor: 1.246

Review 2.  Drugs for the treatment of impotence.

Authors:  L Garcia-Reboll; J P Mulhall; I Goldstein
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

3.  Alpha(1A)-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries.

Authors:  J S Morton; C J Daly; V M Jackson; J C McGrath
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

4.  Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2006

Review 5.  In vitro models: research in physiology and pharmacology of the lower urinary tract.

Authors:  Robert B Moreland
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 6.  Neurotransmission and the contraction and relaxation of penile erectile tissues.

Authors:  K E Andersson; C G Stief
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 7.  Molecular Yin and Yang of erectile function and dysfunction.

Authors:  Ching-Shwun Lin; Zhong-Cheng Xin; Zhong Wang; Guiting Lin; Tom F Lue
Journal:  Asian J Androl       Date:  2008-05       Impact factor: 3.285

8.  Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist.

Authors:  Hiroya Mizusawa; Petter Hedlund; Johan Sjunnesson; Jorge D Brioni; James P Sullivan; Karl-Erik Andersson
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 9.  Effects of alpha(1)-adrenoceptor antagonists on male sexual function.

Authors:  Marleen M van Dijk; Jean J M C H de la Rosette; Martin C Michel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.